Optiscan has been featured in Stockhead's Long Shortz where host Tylah Tully sits down with Optiscan managing director and CEO Dr Camille Farah to discuss the latest milestone in the company’s ACL digital pathology study, with more than 80 patients now imaged using the InForm platform.

He explains how the data will support Optiscan’s planned FDA submission, what sets the technology apart in pathology workflows, and the key catalysts investors should watch for over the next few months.

Watch the full interview here.